Cost per patient of treatment for rifampicin‐resistant tuberculosis in a community‐based programme in Khayelitsha, South Africa-Reference-Cited by-同舟云学术

Cost per patient of treatment for rifampicin‐resistant tuberculosis in a community‐based programme in Khayelitsha, South Africa

Published:2015-06 Issue:10 Volume:20 Page:1337-1345
ISSN:1360-2276
Container-title:Tropical Medicine & International Health
language:en
Short-container-title:Trop Med Int Health

Author:

Cox Helen¹,Ramma Lebogang²,Wilkinson Lynne³,Azevedo Virginia⁴,Sinanovic Edina²

Affiliation:

1. Division of Medical Microbiology and Institute of Infectious Disease and Molecular Medicine University of Cape Town Cape Town South Africa

2. Health Economics Unit University of Cape Town Cape Town South Africa

3. Médecins Sans Frontières (MSF) Khayelitsha South Africa

4. City of Cape Town Health Department Khayelitsha South Africa

Funder

Wellcome Trust

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Parasitology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tmi.12544

Reference24 articles.

1. World Health Organization.Global Tuberculosis Report 2014.World Health Organization Geneva 2014. Contract No.: WHO/HTM/TB/2014.08.

2. A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis

3. Decentralised management of drug‐resistant tuberculosis (MDR‐ and XDR‐TB) in South Africa: an alternative model of care;Padayatchi N;Int J Tuberc Lung Dis,2008

4. National Health Laboratory Service.GeneXpert MTB/RIF Progress Report July 2014.2014.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of drug-resistant tuberculosis treatment outcome in Limpopo province, South Africa;African Journal of Primary Health Care & Family Medicine;2023-07-31

2. Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting–A cost-effectiveness analysis;PLOS ONE;2023-07-14

3. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis;PLOS Global Public Health;2022-12-07

4. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis;2022-11-10

5. Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa;Scientific Reports;2022-06-27